Estrella Immunopharma Statistics
Share Statistics
Estrella Immunopharma has - shares outstanding. The number of shares has increased by -1.18% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.54% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 10.10M |
| Failed to Deliver (FTD) Shares | 3.39K |
| FTD / Avg. Volume | 8.75% |
Short Selling Information
The latest short interest is 6.54K, so 0.02% of the outstanding shares have been sold short.
| Short Interest | 6.54K |
| Short % of Shares Out | 0.02% |
| Short % of Float | 0.06% |
| Short Ratio (days to cover) | 0.07 |
Valuation Ratios
The PE ratio is -5.3 and the forward PE ratio is null.
| PE Ratio | -5.3 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 9.06 |
| P/FCF Ratio | -2.41 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Estrella Immunopharma Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.65, with a Debt / Equity ratio of 0.
| Current Ratio | 24.65 |
| Quick Ratio | 24.65 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.71% and return on capital (ROIC) is -171.09%.
| Return on Equity (ROE) | -1.71% |
| Return on Assets (ROA) | -1.64% |
| Return on Capital (ROIC) | -171.09% |
| Revenue Per Employee | - |
| Profits Per Employee | - |
| Employee Count | - |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 1.63K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 5.45% in the last 52 weeks. The beta is 0.24, so Estrella Immunopharma 's price volatility has been higher than the market average.
| Beta | 0.24 |
| 52-Week Price Change | 5.45% |
| 50-Day Moving Average | 1.04 |
| 200-Day Moving Average | 1.11 |
| Relative Strength Index (RSI) | 49.66 |
| Average Volume (20 Days) | 38.74K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -7.31M |
| Net Income | -7.31M |
| EBITDA | -7.31M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.21 |
Balance Sheet
The company has 4.17M in cash and 0 in debt, giving a net cash position of 4.17M.
| Cash & Cash Equivalents | 4.17M |
| Total Debt | 0 |
| Net Cash | 4.17M |
| Retained Earnings | -19.50M |
| Total Assets | 3.74M |
| Working Capital | -753.71K |
Cash Flow
In the last 12 months, operating cash flow was -16.07M and capital expenditures -4, giving a free cash flow of -16.07M.
| Operating Cash Flow | -16.07M |
| Capital Expenditures | -4 |
| Free Cash Flow | -16.07M |
| FCF Per Share | -0.46 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ESLA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -18.1% |
| FCF Yield | -38.32% |
Analyst Forecast
Currently there are no analyst rating for ESLA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -8.17 |
| Piotroski F-Score | 0 |